What was the sale price for David B. Roberts’ LMAT share transaction?

The reported weighted average sale price was $106.8003 per LMAT share. A footnote explains the sale occurred in multiple trades between $105.85 and $107.30, with full trade-by-trade information available from the company or regulators upon request.

LeMaitre Vascular (LMAT) president reports sale of 8,464 shares

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

LeMaitre Vascular (LMAT) president and director David B. Roberts reported multiple equity transactions. The largest was an open-market sale of 8,464 shares of common stock at a weighted average price of $106.8003 per share, leaving him with 17,979 shares directly owned after that sale.

On the prior day, he acquired common stock through the vesting and settlement of performance share unit (PSU) awards and related dividend equivalent rights, including grants of 1,514 shares and 146 shares at no cost, plus small amounts from dividend equivalents. The company also withheld 134 shares and 13 shares to cover tax obligations upon PSU vesting, which are reported as exempt dispositions.

Insider Trade Summary

Net Seller: 8,464 shares ($903,958)

Net Sell 7 txns

Insider Roberts David B

Role President and Director

Sold 8,464 shs ($904K)

Type	Security	Shares	Price	Value
Sale	Common Stock	8,464	$106.8003	$904K
Exercise	Dividend Equivalent Rights	3	$0.00	--
Grant/Award	Common Stock	1,514	$0.00	--
Grant/Award	Common Stock	146	$0.00	--
Exercise	Common Stock	3	$0.00	--
Tax Withholding	Common Stock	134	$113.69	$15K
Tax Withholding	Common Stock	13	$113.69	$1K

Holdings After Transaction: Common Stock — 17,979 shares (Direct); Dividend Equivalent Rights — 9.38 shares (Direct)

Footnotes (1)

These shares represent LMAT common stock acquired on February 26, 2026, upon settlement of a Performance Share Unit (PSU) award granted on December 6, 2024. The PSU award vested 25% upon determination of satisfaction of the performance condition (on 2/26/2026), and the balance vests in equal annual installments on the grant date anniversary over the next three years. These shares represent LMAT common stock acquired on February 26, 2026, upon settlement of a Performance Share Unit (PSU) award granted on February 18, 2025. The PSU award vested 25% upon determination of satisfaction of the performance condition (on 2/26/2026), and the balance vests in equal annual installments on December 6th over the next three years (2026, 2027 and 2028). Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of PSUs awarded to the reporting person on December 6, 2024. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of PSUs awarded to the reporting person on February 18, 2025. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $105.85 to $107.30. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected. These dividend equivalent rights were released in connection with the vesting of a PSU award granted on December 6, 2024. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

Form 4 Insider Transactions: What Each Field Means →

03/02/2026 - 08:57 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roberts David B

(Last)

(First)

(Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON

01803

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and Director

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/26/2026		A		1,514⁽¹⁾	A	$0	26,444	D
Common Stock	02/26/2026		A		146⁽²⁾	A	$0	26,590	D
Common Stock	02/26/2026		M		3⁽³⁾	A	$0⁽³⁾	26,593	D
Common Stock	02/26/2026		F		134⁽⁴⁾	D	$113.69	26,456	D
Common Stock	02/26/2026		F		13⁽⁵⁾	D	$113.69	26,443	D
Common Stock	02/27/2026		S		8,464	D	$106.8003⁽⁶⁾	17,979	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Dividend Equivalent Rights	⁽⁷⁾	02/26/2026		M			3⁽⁷⁾	⁽⁷⁾	⁽⁷⁾	Common Stock	3	$0	9.38	D

Explanation of Responses:

1. These shares represent LMAT common stock acquired on February 26, 2026, upon settlement of a Performance Share Unit (PSU) award granted on December 6, 2024. The PSU award vested 25% upon determination of satisfaction of the performance condition (on 2/26/2026), and the balance vests in equal annual installments on the grant date anniversary over the next three years.

2. These shares represent LMAT common stock acquired on February 26, 2026, upon settlement of a Performance Share Unit (PSU) award granted on February 18, 2025. The PSU award vested 25% upon determination of satisfaction of the performance condition (on 2/26/2026), and the balance vests in equal annual installments on December 6th over the next three years (2026, 2027 and 2028).

3. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.

4. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of PSUs awarded to the reporting person on December 6, 2024. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.

5. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of PSUs awarded to the reporting person on February 18, 2025. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.

6. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $105.85 to $107.30. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.

7. These dividend equivalent rights were released in connection with the vesting of a PSU award granted on December 6, 2024. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did David B. Roberts report in this Form 4 for LMAT?

David B. Roberts reported an open-market sale of LMAT common stock and several equity award-related transactions. These included PSU vesting, dividend equivalent rights settlement, and shares withheld to cover taxes, all affecting his directly owned share count in LeMaitre Vascular.

How many LeMaitre Vascular (LMAT) shares did David B. Roberts sell?

David B. Roberts sold 8,464 shares of LMAT common stock. The sale was executed as an open-market transaction at a weighted average price of $106.8003 per share, as disclosed in the Form 4 filing’s transaction details and explanatory footnote.

Did David B. Roberts also acquire LMAT shares in this Form 4?

Yes. He acquired LMAT common stock through PSU vesting and dividend equivalent rights settlement. The filing notes grants of 1,514 shares and 146 shares at no cost, plus shares from dividend equivalents tied one-for-one to common stock value.

Why were some LMAT shares reported as disposed of for David B. Roberts?

Some LMAT shares were withheld by the issuer to satisfy tax withholding obligations from PSU vesting. These dispositions, totaling 134 shares and 13 shares, are classified as tax-withholding transactions and are described as exempt sales under Rule 16b-3(e).

What are the dividend equivalent rights mentioned in the LMAT Form 4?

Dividend equivalent rights give David B. Roberts the economic equivalent of LMAT common stock dividends. In this filing, certain rights were released upon PSU vesting, converting to common stock on a one-for-one basis, as described in the footnotes to the Form 4.